A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) ...
Value-based programs, such as the Oncology Care Model (OCM), seek to improve care for patients undergoing chemotherapy, while reducing total costs. The purpose of this study is to quantify the impact ...
Blue Shield of California will purchase Idacio at $525 per dose, significantly cheaper than Humira's $2100 price, enhancing affordability for patients. Collaboration with Fresenius Kabi and Evio ...
2026 JUN 04 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News-- Data detailed on Clinical Oncology have been presented. According to news reporting from Bethesda, Maryland, by ...
The U.S. health-care system is at a crossroads. Generic drugs and biosimilars have the potential to reduce costs and improve access to life-saving treatments, but outdated policies and entrenched ...
The Development: The Food and Drug Administration ("FDA") issued two draft guidance documents that would largely eliminate clinical efficacy and switching studies and instead rely on the precision of ...
A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results